Seeking Alpha26d
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
In the space of non-small cell ... options like osimertinib. However, mutations leading to insertions within exon 20 (of which there are quite a few) tend to be associated with resistance to ...
PharmiWeb22d
Datopotamab deruxtecan granted Priority Review in…
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Acquired resistance to front-line therapies and, ultimately, disease progression are unfortunate realities for most ...
AstraZeneca PLC: Imfinzi recommended for EU approval for LS-SCLC
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...
pharmaphorum8d
J&J doublet beats Tagrisso in first-line lung cancer
AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung ... than Tagrisso (osimertinib) on its ...
pharmaphorum3d
FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag
Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer ... as well as a resistance mechanism that tumours can ...
BioSpace22d
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Acquired resistance to front-line therapies and, ultimately, disease progression are unfortunate realities for most ...